Outlook Therapeutics resubmits biologics license application for ONS-5010

Outlook Therapeutics resubmitted a biologics license application to the FDA for ONS-5010 for the treatment of neovascular age-related macular degeneration, according to a press release. The company successfully appealed a 2025 complete response letter for ONS-5010 (bevacizumab-vikg, bevacizumab gamma), also known as Lytenava, and the FDA confirmed that effectiveness of the treatment has been